Fax: 404.778.3180
1991-1992 National Parkinson Foundation Research Award for work at Emory
Positions and Employment
1977-1980 Medical Residency, Columbia University, Roosevelt Hospital, NYC
1980-1983 Neurology Resident, Harvard Medical School, Mass. General Hospital, Boston
1981-1982 Neuropharmacology Research, Department of Neurology, Harvard Medical School
1983-1985 NIH Medical Staff Fellow, Experimental Therapeutics Branch, Neuropharmacology Research
1985-1987 NIH Senior Staff Fellow Experimental Therapeutics Branch, Movement Disorders Clinic
1987-1988 Visiting Fellow in Neurochemistry and Neuropathology, INSERM U-289 Hôpital de La
Salpétrière, Paris, France
1988-1996 Assistant Professor of Neurology, Emory University
1994-1998 Chief, Section of Neurology, Wesley Woods Geriatric Center
1994- Assistant Professor of Gerontology, Emory University
1996- Associate Professor of Neurology, Emory University
1998- Director, Wesley Woods Hospital Neurology Inpatient Unit
1988- Staff Neurologist - The Emory Clinic, Emory University Hospital, Wesley Woods Hospital and
Health Center, Grady Memorial Hospital, Crawford Long Memorial Hospital
1988- Co-Director, Emory University, Movement Disorders Program
2003- Medical Director, Emory University American Parkinson‚s Disease Association Information and Referral Center
Other Experience and Professional Memberships
1984-1987 NIH Biostatistic Training - one course/academic semester
1992- Ad-Hoc Reviewer for Movement Disorders Journal
1989- Ad-Hoc Reviewer for Annals of Neurology
1994 Ad-Hoc Reviewer for NIH General Clinical Research Center (GCRC) Study Section
1990- Medical Advisory Board, Tourette Syndrome Association of Georgia and South Carolina
1998- Board, American Parkinson Disease Association, Georgia chapter
2001- Tourette Syndrome Association, National Medical Advisory Board
Ongoing Research Support
1 RO-1 AT00612-03 Juncos (PI) 8/01/00-06/30/05 (NCE)
NIH-Emory NCAAM
Chinese exercise modalities and motor control in Parkinson‚s disease
This is a double-blind, placebo-controlled study comparing the effects of three exercise modalities on peripheral and central indices of motor control in PD. The modalities are Qi-Gong, Tai-Chi and a walk-run cardiovascular fitness program. This project is in a No Cost Extension
Role: PI
CAM Center Grant 5 P30AT00609-03 8/01/00-06/30/05
DeLong:P.I. Center Grant
Juncos: CAM Center Community Liaison for Developmental Projects
Pilot Projects Funded through a Development Fund from the Medical School Dean to the CAM Center
Pilot Project 3 Juncos (PI) 05/01/03-04/22/05
Creatine monohydrate supplementation in Parkinson‚s disease: A pilot study in patients undergoing resistance training. Dr. Juncos holds an IND on the use of creatine for this investigational purpose.
Role: PI
2PO1HD3557604A1 Sherman (PI) 09/18/01-06/30/06
NIHCHD
A study of the ataxia/tremor phenotype as a possible late presentation of the Fragile X premutation in cases with intermediate trinucleotide repeat lengths
This study will examine the validity of this proposed tremor-ataxia premutation phenotype by examining patients with this phenotype from within and from outside identified pedigrees with the full FX syndrome in an effort to validate its validity. Clinical, neuropsychologic and genetic correlations are the core of this proposal.
Role: Investigator
NDPCS FS01-2002 Kieburtz (PI) 07/01/03-6/30/08
NIH NINDS
A multi-center, double blind, pilot study of CoQ10 and GPI 1485 in subjects with early untreated PD
The primary objective of these studies is to assess the impact of purported neuroprotective treatments on the progression of PD. The immediate aim is to assess whether it is non-futile to proceed with further study of these agents. The progression of PD will be measured by the change in total UPDRS score between the baseline visit and month 12, or the time to reach sufficient disability to require symptomatic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first.
Role: Site Investigator
ACADIA Pharmaceuticals, Inc. Friedman (PI) 5/1/04 ˆ 4/30/05
This is a Phase 2 study of ACP-103, a serotonin receptor inverse agonist in the treatment of psychosis in Parkinson‚s disease.
Role: Site Investigator
Berlex Laboratories and Titan Pharmaceuticals Watts (PI) 12/01/02 ˆ 11/30/05
Protocol #305405
Spheramine (gelatin encapsulated retinal epithelial cells) in Parkinson‚s disease (STEPS)
Study of the safety, tolerability and efficacy of Spheramine® implanted bilaterally into the post commissural putamen in patients with advanced Parkinson‚s disease.
Role: Site Investigator
Dar Pharma Juncos (PI) 1/01/02-7/2/05
A Phase I-II controlled, single site study of the safety and efficacy of parenteral dihydrexidine (a dopamine D1 agonists) in advanced Parkinson‚s disease. Dr. Juncos holds an IND on this compound.
Role: PI
American Parkinson‚s Disease Association DeLong (PI) 6/1/03 - 8/31/05
Center for Excellence in Parkinson‚s Disease Research
Current projects: Pilot project on the use of acetylcholinesterase inhibitors and memantine for cognitive impairment and hallucinations in PD. Support was also used to complete comprehensive reviews of PD and other movement disorders for Harrison‚s Chapter of Internal Medicine, Scientific American Medicine and Medicine for the Practicing Physician.
Role: Investigator
Novartis Pharmaceuticals, Inc. Juncos (PI) 8/01/04-7/31/05
A Placebo-controlled, Crossover Study Comparing the Acute Cognitive Effects of Stalevo to Equivalent Doses of Dopamine Agonists
To compare the effects of Stalevo and dopamine agonists on selected aspects of mental function in patients with Parkinson‚s disease.
Role: PI
Kyowa and Lineberry Research Associates, LLC Juncos (PI) 7/1/2004-6/10/2005
Protocol No. 6002-US-018
A 12-week, Double-Blinded, Placebo-Controlled, Randomized, Parallel-Group, Multicenter, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10,20 and 40 mg/d Oral Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy
Role: PI
Kyowa and Lineberry Research Associates, LLC Juncos (PI) 11/1/2004-12/30/2006
Protocol No. 6002-INT-001
A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa Therapy.
Role: PI
SAD-PD Richard (PI) 3/1/05 ˆ 6/30/07
NIH NINDS
Serotonergic anti-depressants in Parkinson‚s disease
A 12 week, controlled study of SSRIs in patients with Parkinson‚s disease and depression to examine the efficacy of two types of antidepressants, venlafaxine (Effexor XR) and paroxetine (Paxil).
Role: Site Investigator
Pending Research Support
Norvartis Pharmaceuticals, Inc.
STRIDE-PD
A Long-term, Double-Blind, Randomized, Parallel-Group, Carbidopa/Levodopa Controlled, Multi-Center Study to Evaluate the Effect of Stalevo in Patients with Parkinson‚s Disease Requiring Initiation of Levodopa Therapy
Role: Site Investigator
Publications
Scientific Journals:
Juncos JL, Yeung P, Sweitzer D, Arvanitis L, Nemeroff C. Quetiapine improves psychotic symptoms associated with Parkinson’s disease. Neurology 2004. Under review.
Alvarez L, Marcias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, Juncos JL, Maragoto C, Guridi J, Litvan I, Tolosa ES, Koller W, Vitek J, DeLong MR, Obeso JA. Bilateral Dorsal Subthalamotomy in Parkinson’s Disease: initial response and long-term evolution. Submitted.
Hass CJ, Waddell DE, Wolf SL, Juncos JL, Gregor RJ. Momentum and stability during bi-directional gait initiation in older adults and in patients with Parkinson’s disease. Submitted.
Pahwa R, Lyons KE (Juncos JL contributed to the Manuscript developed through the Tremor Research Group). Essential Tremor: differential diagnosis and current therapy. Am J Med 2003;115:134-142.
Okun MS, Raju DV, Walter BL, Juncos JL, DeLong MR, Heilman K, McDonald WM, Vitek JL. Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004;75(6):921-3.
Chapters in Textbooks:
DeLong MR, Juncos JL. Parkinson’s Disease and other movement disorders. Harrison’s Principles of Internal Medicine 16th Edition. New York: McGraw-Hill, Inc., 2004. In press.
Juncos JL, Freeman A. Pathophysiology and differential diagnosis of tics. In: Watts RL, Koller WC, eds. Movement Disorders: Neurologic Principles and Practice. New York: McGraw Hill, Inc., 2004:69701.